

To: 'a.r.schnatter@exxonmobil.com' <a.r.schnatter@exxonmobil.com>;
r.jeffrey.lewis@exxonmobil.com <r.jeffrey.lewis@exxonmobil.com>
From: Cagen, Stuart Z SCC-DCS/261
</O=SHELL/OU=MSXSCC/CN=RECIPIENTS/CN=SC724012>
Cc:
Bcc:
Received Date: 2005-12-16 21:37:12 GMT
Subject: RE: BD peer reviewers

I would go beyond the quest for leukemia experts. How about dose response experts or those who can appreciate an epidemiology study with a good exposure assessment.

Roy Shore might have a previous BD connection, but eligibility rules (and how long they apply) are not yet firm.

Other possibilities:

Dr. Jerry M. Rice, (Chair), IARC (Retired) Not eligible: Prior BD via IARC
Dr. Nancy Mueller (Vice Chair), Harvard University, School of Public Health
Dr. Harvey Checkoway, Washington University Prior BD research experience
Dr. Helmut Greim, Technical U. of Munich
Dr. Howard Rockette, University of Pittsburgh
Dr. John Cherrie, Aberdeen University, Institute of Occupational Medicine Possible not eligible as he was a reviewer of a BD air standard in the UK (Link to the UK Air quality Standard document on BD http://www.defra.gov.uk/environment/airquality/aqs/13butad_2nd/pdf/epaqs_13butad-2nd_full.pdf)

Dr. Robert F. Herrick, Harvard University, School of Public Health
Dr. Richard Larson, University of Chicago Medical School
Dr. Mark Minden, University of Toronto
Dr. Li Guilan, Academy of Preventive Medicine, China
Dr. Richard Albertini, University of Vermont, College of Medicine Not eligible: BD researcher and Risk assessment co-author

Stuart Cagen

Shell Chemical LP
One Shell Plaza, 910 Louisiana, Houston, TX 77002-4916

Tel: +1 713 241 1407 Fax: 3325 Other Tel: +1 832 646 3987
Email: stuart.cagen@shell.com
Internet: <http://www.shell.com/chemicals>

"Business Success through HSSE Excellence"

-----Original Message-----

From: a.r.schnatter@exxonmobil.com [mailto:a.r.schnatter@exxonmobil.com]
Sent: Friday, December 16, 2005 3:08 PM
To: r.jeffrey.lewis@exxonmobil.com
Cc: Elizabeth_Moran@americanchemistry.com; Cagen, Stuart Z SCC-DCS/261
Subject: Re: BD peer reviewers

I'm not sure whether leukemogenesis experts are really needed. Most of them will support Irons' view that chemicals causing both types of

leukemias are pretty rare, if they exist at all. If I'm over-ruled, Richard Larson (from the Shanghai SAB) is excellent, so is John Bennett. I would also strongly recommend Roy Shore, a statistician more familiar with BD and Sielken-type risk modelling.

A. Robert Schnatter
ExxonMobil Biomedical Sciences, Inc.
Room LF-246
545 Route 22 East
Annadale, NJ 08801-0971
908-730-1101
908-730-1192(fax)

R Jeffrey
Lewis/East-US/
ExxonMobil
To
A R Schnatter/East-US/ExxonMobil@xom
cc
12/16/05 02:10
PM
Subject
BD peer reviewers

Rob,

At the end of the BD workgroup call today, Stuart asked if any the folks on the Shanghai study advisory board might be good candidates for the BD peer review. Stuart mentioned someone named Howard Rocket, but thought there would be others too. Experts in leukemogenesis and statistics are what is really needed most.

Jeff

R. Jeffrey Lewis
ExxonMobil Biomedical Sciences, Inc.
Epidemiology & Health Surveillance Section
1545 Route 22 East, P.O. Box 971
Room LF 264
Annandale, NJ 08801-0971
(908)730-1107 (voice)
(908)730-1192 (fax)
(732)437-0670 (pager)
r.jeffrey.lewis@exxonmobil.com

This document and all information contained within this electronic message

SHELL-MCCLURG-054968

may be privileged, confidential, and exempt from disclosure under applicable law. It is intended only for the use of the individual(s) and/or entity(ies) named above. If you are not the intended recipient, you are on notice that any unauthorized disclosure, copying, distribution, or taking of any action in reliance on the contents of the electronically transmitted materials is prohibited.
